Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

Gilead on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers lenacapavir for use as pre-exposure prophylaxis, or PrEP, to reduce ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit ...

In June 1981, news of a mysterious disease first began making headlines out of San Francisco, Los Angeles and New York. People who were impacted developed unusual infections and grew sick as their ...

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead Sciences, Hookipa Pharma has ...

Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...

Gilead Sciences Inc. closed 9.09% short of its 52-week high of $119.96, which the company achieved on March 10th.